Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + chemotherapy
pembrolizumab + chemotherapy · Merck Sharp & Dohme
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Locally recurrent unresectable or metastatic triple-negative breast cancer with PD-L1 combined positive score of at least 10 on an FDA-approved test, in combination with chemotherapy.
LAMPGEN ANALYSIS
Why it matters
Added a checkpoint inhibitor to chemotherapy for a PD-L1-selected advanced TNBC population under accelerated approval.
What research teams should watch
Capture the combined positive score and chosen chemotherapy regimen and distinguish immune from chemotherapy toxicities.
PRIMARY RECORDS